samedan logo
 
 
 
spacer
home > ebr > autumn 2020 > boston diary – day 144
PUBLICATIONS
European Biopharmaceutical Review

Boston Diary – Day 144

When I wrote my last column, ‘Run for the Roses’, the race for a COVID-19 vaccine was just getting underway. Now, the preliminary reports are coming in almost daily. Multiple projects, featuring diverse technologies, show early and encouraging progress. Large-scale clinical trials will demonstrate how well the different approaches work in large numbers of people. While the candidates apparently do elicit antibodies, one key question is effectiveness. Will the vaccine provide immunity; in what fraction of the population; and for how long? Achieving herd immunity for COVID-19 is estimated to require an immunity rate somewhere between that of flu and measles vaccines – and we still face significant unknowns in production and distribution.

As a time-honoured stop-gap measure, many hospitals throughout the world have turned to convalescent blood plasma for the more serious cases. Anecdotally, it has provided improvement in patient outcomes and did not potentiate cytokine storms. Post hoc analysis of immunoglobulin G quantitation and patient outcomes for matched subjects strongly suggest efficacy. However, donor plasma is a limited commodity. A number of biopharmaceutical companies have launched programmes to develop synthetic antibodies, which can complement vaccine therapy if they can be made cost-effective.

The soothsayer in Shakespeare’s play, Julius Caesar, was on my mind as the COVID-19 pandemic began to spread. The ‘Ides of March’ arrived, and my office started to work from home. In our region, as in many others, our state government provided guidelines for social distancing, business closures – except for essential operations – and other public health measures. The savings in auto mileage and daily commute time did have a certain appeal. Online meetings soon became the new normal. However, the excessive, back-to-back web meetings every morning get a little tedious.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board, a graduate of the Harvard Business School, US, and an industry consultant with experience in the biotech and biopharma industry.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Stoelzle pursues their path towards establishing sustainably long-term success

Being sustainably successful as an international enterprise for Stoelzle means acting responsibly, improving the working conditions and quality of life of our employees, as well as securing the opportunities of future generations. So we have a clear picture in mind when managing the company: our goal is to sustainably increase the value of the Stoelzle Glass Group from an ecological, social and economic perspective.
More info >>

White Papers

Quality Systems Guide

Research Quality Association

This guide concentrates on the core, underlying principles of quality that are pivotal – explicitly or implicitly – to all quality management standards that impact on research and development.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement